Calcipotriol;Le calcipotriol

Annales de Dermatologie et de Venereologie

Volumn 128, Issue 3 I, 2001, Pages 229-237

  Guilhou, J J ^a  

^a HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APSCOR; CALCIPOTRIOL; CALCITRIOL; CALCIUM; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; PHOSPHORUS; RETINOID; TACALCITOL; VITAMIN D DERIVATIVE;

ARTICLE; CALCIUM METABOLISM; CONTACT DERMATITIS; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSKERATOSIS; HUMAN; HYPERCALCEMIA; ICHTHYOSIS; PHOSPHATE METABOLISM; PHOTOSENSITIZATION; PHOTOTHERAPY; PSORIASIS; SCLERODERMA; SKIN MANIFESTATION; STRUCTURE ACTIVITY RELATION; ULTRAVIOLET B RADIATION; VITILIGO;

CALCITRIOL; DERMATOLOGIC AGENTS; HUMANS;

EID: 0035044698     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. 3 treatment in psoriasis vulgaris
2. 3 analogue (MC 903) in a double-blind study
3. The concept of multiple vitamin D signaling pathways
4. Origin of the use of calcipotriol in psoriasis treatment
5. 3 and its synthetic derivatives MC 903 and EB1089 induce a partial skin-equivalent system
6. Vitamin D, immune system and skin
7. 3 and its analogue calcipotriol on epidermal cells
8. 3, analogs
9. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions
10. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin
11. 3, tacalcitol, and calcipotriol after topical treatment in rats
12. Toxicokinetics of topically applied calcitriol and calcipotriol in rats
13. Urine calcium excretion during treatment of psoriasis with topical calcipotriol
14. The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis
15. 3
16. 3H-calcipotriene following multiple dose treatment with non-radiolabeled calcipotriene 0.005 % ointment
17. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis
18. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris: A randomized, double-blind, right/left comparative, vehicle-controlled study
19. Comparative efficacy of calcipotriol (MC 903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study
20. Calcipotriol cream with of without concurrent topical corticosteroid in psoriasis: Tolerability and efficacy
21. Comparative effects of two different calcipotriol (MC 903) cream formulations versus placebo in psoriasis vulgaris. A randomized, double-blind, placebo-controlled, parallel group multi-centre study
22. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris
23. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris
24. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis
25. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis
26. A randomized double-blind comparison of the effects on systemic calcium homeostasis of topical calcitriol (3μg/g) and calcipotriol (50 μg/g) in the treatment of chronic plaque psoriasis vulgaris
27. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial
28. Treatment of psoriasis with calcipotriol: Time of onset and healing of relapses
29. Comparison ora treatment phase and a follow-up phase of short-contact dithranol and calcipotriol in outpatients with chronic plaque psoriasis
30. Long-term use of topical calcipotriol in chronic plaque psoriasis
31. Psoriasis: Nouvelle modalité thérapeutique par le calcipotriol plus le dipropionate de bêtaméthasone
32. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: Effects on the duration of improvement
33. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks
34. Topical calcipotriol combined with phototherapy for psoriasis
35. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: A safe, effective and UVB-sparing antipsoriatric combination treatment
36. Combination phototherapy of psoriasis with calcipotriol and narrow-band UVB
37. No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis
38. Calcipotriol in combination with PUVA: A randomized double-blind placebo study in severe psoriasis
39. Treatment of psoriasis with calcipotriene plus psoralen-UV-a-bath therapy
40. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cydosporine: Results of a multicenter placebo-controlled study
41. Clinical trial of the efficacy and safety of oral etretinate with calcipotriol cream compared with etretinate alone in moderate-severe psoriasis
42. The effect of addition of calcipotriol ointment (50 μg/g) to acitretin therapy in psoriasis
43. 903) in the treatment of psoriasis of the scalp
44. Comparative effects of calcipotriol solution (50 μg/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis
45. Topical calcipotriol in the treatment of intertriginous psoriasis
46. Calcipotriol ointment in nail psoriasis: A controlled double-blind comparison with betamethasone dipropionate and salicylic acid
47. Acrodermatitis continua of Hallopeau: Response to combined treatment with acitretin and calcipotriol ointment
48. Successful treatment for acrodermatitis continua of Hallopeau using topical calcipotriol
49. The clinical effect of topical calcipotriol in acrodermatitis continua of Hallopeau
50. Safety and efficacy of calcipotriol ointment (Dovonex®) in treating children with psoriasis vulgaris
51. Topical calcipotriol in childhood psoriasis
52. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization
53. Effect of topical calcipotriol on congenital ichthyoses
54. Successful treatment of Grover's disease with calcipotriol
55. Keratosis lichenoides chronica: Response to topical calcipotriol
56. Topical treatment of pityriasis rubra pilaris with calcipotriol
57. Treatment of inflammatory linear verrucous epidermal naevus with calcipotriol
58. Disseminated superficial actinic porokeratosis responding to calcipotriol
59. Topical calcipotriene for morphea/linear scleroderma
60. Treatment of vitiligo with topical calcipotriol
61. Combination of PUVAsol and topical calcipotriol in vitiligo
62. Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of prurigo nodularis
63. 3) in seborrheic keratosis
64. Calcipotriol and regression in T-cell lymphoma of skin
65. Topical calcipotriol treatment in advanced breast cancer
66. Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis
67. Pourquoi le calcipotriol irrite-t-il le visage?
68. Allergic contact dermatitis to calcipotriol
69. Eczema de contact au calcipotriol
70. Contact dermatitis after calcipotriol and patch test evaluation
71. Patch test study with calcipotriol ointment in different patient groups, including psoriatic patients with and without adverse dermatitis
72. Interactions between calcipotriene and ultraviolet light
73. Calcipotriol ointment and cream or their vehicles applied immediately before irradiation inhibit ultraviolet B-induced erythema
74. Does addition of topical calcipotriol to UVB increase the risk of irritant reactions in psoriasis?
75. Photosensitivity associated with combined UV-B and calcipotriene therapy
76. Hyperpigmentation due to topical calcipotriol and photochemotherapy in two psoriasis patients
77. 903) plus heliotherapy in psoriatic patients